Malignant Glioma Clinical Trial
Official title:
Effects of Low Dose Naltrexone on Quality of Life in High Grade Glioma Patients: A Placebo-Controlled, Double-Blind Randomized Trial
To compare the effects of low dose naltrexone (LDN) versus placebo on quality of life in high grade glioma patients undergoing standard chemoradiation
The proposed study is a placebo-controlled, randomized clinical trial. Potential
participants will be identified via clinical protocol chart review of patients scheduled to
attend their predetermined follow-up consultations at The Preston Robert Tisch Brain Tumor
Center (PRT-BTC) at Duke University Medical Center after evaluation of treatment for newly
diagnosed high grade gliomas. We will identify high grade glioma patients that will receive
standard chemoradiation (radiotherapy with daily temozolomide dosed at 75 mg/m2). After
obtaining written informed consent, all participants will be scheduled for baseline study
assessments before starting radiotherapy. Patients will be randomized to receive either
placebo or low dose naltrexone (LDN) dosed at 4.5 mg orally to be taken every evening before
going to bed. Patients will be assessed at the following time points: 1. Baseline (before
chemoradiation), 2. After chemoradiation (approximately 8 weeks from initial assessment), 3.
Two months after standard chemoradiation (approximately 16 weeks after initial assessment),
and 4. Four months after standard chemoradiation (approximately 24 weeks after initial
assessment). Treatment with LDN or placebo will begin on first day of chemoradiation and
will be continued for a total of 16 weeks from initial assessment. Last assessment at 24
weeks will occur 8 weeks after discontinuation of LDN or placebo. All visits will be linked
to patients' clinical management visits. All testing will be performed at PRT-BTC and at
Duke University Medical Center.
The following procedures will be obtained at each assessment visit:
1. Complete a six-minute walk test. The exercise test is designed to determine how far the
subject can walk in six minutes. This test will take place at the PRT-BTC at Duke
University Medical Center with appropriate medical supervision.
2. Blood testing that will be performed as part of each clinic visit. Approximately 10
milliliters or 2 teaspoons of blood will be drawn at each visit. This will not be
additional blood work, but rather the standardized blood work that the subject will
need for evaluation associated with radiation and chemotherapy treatments.
We will ask the subject to complete the following tests/questionnaires:
1. Neurocognitive testing: this testing will be performed using a computer program called
CNS Vital Signs®. This program consists of verbal and visual memory tests, attention
tests, reasoning tests, and speed of processing tests. The subject will use a laptop
computer to complete these tests. No previous exposure to computers or computer testing
is needed to complete the test.
2. Computerized Questionnaires: Four questionnaires will be presented using a computerized
program. These will include Medical Outcomes Survey (MOS), Epworth Sleepiness Scale
(ESS), Pittsburgh Sleep Quality Index (PSQI), and Zung Self-Rating Depression Scale
(ZSDS). MOS assesses general health, well-being, and quality of life. ESS asks about
level of sleepiness while PSQI asks about sleep quality. Finally, ZSDS will evaluate
feelings of depression and sadness.
3. Beck depression inventory (BDI): This questionnaire asks questions about the subject's
levels of sadness, changes in the subject's mood, sleeping and eating patterns, the
subject's level of interest in activities, thoughts and feelings the subject is having
and the subject's level of concentration. This is a pen and paper questionnaire.
4. Functional Assessment of Cancer Therapy-Brain (FACT-BR) scale: This questionnaire asks
questions about physical, function, emotional, and social well-being. This is a pen and
paper questionnaire.
5. Functional Assessment of Cancer Therapy-Fatigue (FACIT-F) scale: This questionnaire
asks questions about fatigue. This is a pen and paper questionnaire.
6. Functional Assessment of Cancer Therapy-Cognition (FACT-Cog) scale: This questionnaire
asks questions about your thinking and ability to do memory, attention, and reasoning
activities. This is a pen and paper questionnaire.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02764151 -
First in Patient Study for PF-06840003 in Malignant Gliomas
|
Phase 1 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Completed |
NCT00953121 -
Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)
|
Phase 2 | |
Completed |
NCT00766467 -
A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas
|
Phase 2 | |
Active, not recruiting |
NCT03233204 -
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Recruiting |
NCT05045027 -
Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma
|
Early Phase 1 | |
Completed |
NCT02507583 -
Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma
|
Phase 1 | |
Completed |
NCT04109209 -
Psychological Intervention For Brain Tumor Caregivers
|
N/A | |
Recruiting |
NCT04937413 -
The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation
|
Early Phase 1 | |
Completed |
NCT03615404 -
Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma
|
Phase 1 | |
Active, not recruiting |
NCT04175301 -
Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas.
|
Phase 2 | |
Terminated |
NCT02659800 -
Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas
|
Phase 1 | |
Active, not recruiting |
NCT02323880 -
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
|
Phase 1 | |
Completed |
NCT00782756 -
Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
|
Phase 2 | |
Terminated |
NCT02855086 -
Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT02861222 -
Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant Glioma
|
Phase 1 | |
Completed |
NCT00634231 -
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
|
Phase 1 | |
Completed |
NCT01792505 -
Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma
|
Phase 1 | |
Completed |
NCT00190723 -
A Study of LY317615 in Patients With Brain Tumors
|
Phase 2 | |
Recruiting |
NCT04323046 -
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
|
Phase 1 |